 |
인쇄하기
취소
|
KFDA to approve GSK's Requip.
GSK Korea announced that the KFDA approved Requip (ropinirole Hcl) tablet for the adult patient treatment with a moderate and severe primary RLS (restless leg syndrome), which is first in Korea.
Requip was authorized by the U. S. FDA to sell in May this year for the treatment of moderate-to-severe primary RLS.
REQUIP is a 2nd generation of Dopamine agonist directly stimulating the dopam...
Requip was authorized by the U. S. FDA to sell in May this year for the treatment of moderate-to-severe primary RLS.
REQUIP is a 2nd generation of Dopamine agonist directly stimulating the dopam...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.